EYPT
NASD EyePoint, Inc.$3.40 ↑ +0.00 (+0.02%) Trading Up from the previous close of $3.40, $0.17 below the day’s high of $3.57
- YTD change
- -81.39%
- vs 20-day SMA
- -5.66%
- vs 200-day SMA
- -72.26%
Price ranges
Price & Performance
-10.77 (-75.69%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 91.4% away from all-time highs of $39.40
- EYPT is down 81% since the beginning of the year
- EYPT is down 76% over the past 12 months
- EYPT is down 20% over the past 1 month
- 23% of all EYPT investors are betting against EYPT
EYPT reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -75.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.08
- Last 5 days
- +5.28%
- vs 8-day SMA
- +3.56%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.